NAMUR, Belgium, Feb. 23,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX)
today announced that it will attend the BTIG 2017 Medical
Technology, Life Sciences, and Diagnostics Conference being held
from February 28th - March 3rd, 2017
in Snowbird, UT.
Scott Powell, Executive Vice
President of Volition, will provide an update on Volition's
business, clinical, regulatory and operational milestones, as well
as the Company's recently announced product launch of its
Nu.QTM Colorectal Cancer Screening Triage Test.
Persons attending the conference who would like to schedule a
1-on-1 meeting with Volition management during the conference may
do so by contacting Tirth Patel of
Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of
Volition, at S.Powell@volitionrx.com.
Check out the NEW Corporate Video and Website at
www.volitionrx.com
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid --
an indication that disease is present.
As cancer screening programs become more and more widespread,
our products can help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
New York, and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition L.day@volitionrx.com
+44 (0)7557 774620
|
Scott Powell,
Volition S.powell@volitionrx.com
+1 (646) 650 1351
|
|
|
Tirth Patel,
Edison Advisors tpatel@edisongroup.com
+1 (646) 653 7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077 5711
|
|
|
Sarah Roberts,
Vane Percy & Roberts sarah@vanepercy.com
+44 (0)1737 821 890
|
|
Nucleosomics®, NuQ®, Nu.QTMand HyperGenomics® and and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-the-btig-2017-medical-technology-life-sciences-and-diagnostics-conference-300412195.html
SOURCE VolitionRx Ltd.